Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for Giredestrant in Early-Stage ER-Positive Breast Cancer Under Priority Review
2
Montelukast Prophylaxis Reduces Rituximab Infusion Reactions in Oncology Patients
3
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
4
High-Risk, Low-Benefit Treatments for Chronic Low Back Pain Demand Re-Evaluation
5